ONKURE THERAPEUTICS, INC. Debt Securities, Available-for-sale, Amortized Cost
ONKURE THERAPEUTICS, INC. (OKUR) had Debt Securities, Available-for-sale, Amortized Cost of $9.90 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2026-08-04
- 2026-06-30: Debt Securities, Available-for-sale, Amortized Cost $9.90M.
- 2024-09-30: Debt Securities, Available-for-sale, Amortized Cost $15.98M.
- 2024-06-30: Debt Securities, Available-for-sale, Amortized Cost $53.56M.
- 2024-03-31: Debt Securities, Available-for-sale, Amortized Cost $62.45M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2026-06-30 | $9.90M 10-Q · filed 2026-08-04 |
| 2024-09-30 | $15.98M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $53.56M 10-Q · filed 2024-08-13 |
| 2024-03-31 | $62.45M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $75.32M 10-Q · filed 2024-11-07 |
| 2023-09-30 | $113.90M 10-Q · filed 2023-11-13 |
| 2023-06-30 | $133.63M 10-Q · filed 2023-08-10 |
| 2023-03-31 | $63.38M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $81.29M 10-K · filed 2024-03-28 |
| 2021-12-31 | $23.01M 10-K · filed 2023-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |